| FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... New England Journal of Medicine 379 (25), 2395-2406, 2018 | 2418 | 2018 |
| Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009 | 856 | 2009 |
| Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II G Malamut, P Afchain, V Verkarre, T Lecomte, A Amiot, D Damotte, ... Gastroenterology 136 (1), 81-90, 2009 | 433 | 2009 |
| Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis T Lecomte, A Berger, F Zinzindohoué, S Micard, B Landi, H Blons, ... International journal of cancer 100 (5), 542-548, 2002 | 386 | 2002 |
| Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy T Lecomte, JM Ferraz, F Zinzindohoué, MA Loriot, DA Tregouet, B Landi, ... Clinical Cancer Research 10 (17), 5880-5888, 2004 | 329 | 2004 |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031, 2014 | 261 | 2014 |
| Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy T Lecomte, B Landi, P Beaune, P Laurent-Puig, MA Loriot Clinical Cancer Research 12 (10), 3050-3056, 2006 | 258 | 2006 |
| Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly … T Aparicio, JL Jouve, L Teillet, D Gargot, F Subtil, V Le Brun-Ly, J Cretin, ... Journal of Clinical Oncology 31 (11), 1464-1470, 2013 | 235 | 2013 |
| Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study A Zaanan, L Costes, M Gauthier, D Malka, C Locher, E Mitry, D Tougeron, ... Annals of Oncology 21 (9), 1786-1793, 2010 | 192 | 2010 |
| Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected … T Conroy, P Hammel, M Hebbar, M Ben Abdelghani, AC Wei, JL Raoul, ... Journal of Clinical Oncology 36 (18_suppl), LBA4001-LBA4001, 2018 | 190 | 2018 |
| Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort A Portal, S Pernot, D Tougeron, C Arbaud, AT Bidault, ... British journal of cancer 113 (7), 989-995, 2015 | 184 | 2015 |
| Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study D Tougeron, G Mouillet, I Trouilloud, T Lecomte, R Coriat, T Aparicio, ... Journal of the National Cancer Institute 108 (7), djv438, 2016 | 172 | 2016 |
| Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study A Attar, D Malka, JM Sabaté, F Bonnetain, T Lecomte, T Aparicio, ... Nutrition and cancer 64 (4), 535-542, 2012 | 167 | 2012 |
| RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study JB Bachet, O Bouché, J Taieb, O Dubreuil, ML Garcia, A Meurisse, ... Annals of Oncology 29 (5), 1211-1219, 2018 | 156 | 2018 |
| Refractory coeliac sprue is a diffuse gastrointestinal disease V Verkarre, V Asnafi, T Lecomte, NP Mariaud-de Serre, M Leborgne, ... Gut 52 (2), 205-211, 2003 | 156 | 2003 |
| Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome T Lecomte, C Cellier, T Meatchi, JP Barbier, PH Cugnenc, R Jian, ... Clinical Gastroenterology and Hepatology 3 (9), 897-902, 2005 | 153 | 2005 |
| Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy N Ceze, G Thibault, G Goujon, J Viguier, H Watier, E Dorval, T Lecomte Cancer chemotherapy and pharmacology 68, 1305-1313, 2011 | 130 | 2011 |
| Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 127 | 2013 |
| Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract … J Taieb, E Mitry, V Boige, P Artru, J Ezenfis, T Lecomte, MC Clavero-Fabri, ... Annals of oncology 13 (8), 1192-1196, 2002 | 126 | 2002 |
| Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis F Coulet, H Blons, A Cabelguenne, T Lecomte, O Laccourreye, D Brasnu, ... Cancer research 60 (3), 707-711, 2000 | 124 | 2000 |
